2019;20:1239–51. 2. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P , Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J Clin Oncol. 2022;40:127–37. 3. Wei SC, Duffy CR, Allison JP . Fundamental mechanisms of immune check - point blockade therapy. Cancer Discov. 2018;8:1069–86. 4. Kim JY, Kronbichler A, Eisenhut M, Hong SH, van der Vliet HJ, Kang J, Shin JI, Gamerith G. Tumor mutational burden and efficacy of immune check - point inhibitors: a systematic review and meta-analysis. Cancers (Basel). 2019;11:1798. 5. McGranahan N, Furness AJS, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, et al. Clonal neoanti- gens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science.